Keros Therapeutics (KROS) Receivables - Other (2019 - 2021)
Keros Therapeutics posted quarterly Receivables - Other of $100000.0 for Q2 2021, down 87.58% on a QoQ basis from $805000.0 in Q1 2020.
Keros Therapeutics (KROS) has 3 years of Receivables - Other data on file, last reported at $100000.0 in Q2 2021.
- For the quarter ending Q2 2021, Receivables - Other changed N/A year-over-year to $100000.0; the trailing twelve-month figure through Jun 2021 stood at $100000.0 (changed N/A YoY), and the FY2019 full-year result was $900000.0, changed N/A from the prior year.
- Receivables - Other for Q2 2021 stood at $100000.0, down from $805000.0 in the prior quarter.
- Across five years, Receivables - Other topped out at $900000.0 in Q4 2019 and bottomed at $100000.0 in Q2 2021.
- The 3-year median for Receivables - Other is $805000.0 (2020), against an average of $601666.7.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Keros Therapeutics | 403.85 Mn | 116.45 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 100,000.00 |
| Jun 30, 2021 | 100,000.00 |
| Mar 31, 2020 | 805,000.00 |
| Mar 31, 2020 | 805,000.00 |
| Dec 31, 2019 | 900,000.00 |
| Dec 31, 2019 | 900,000.00 |